HIV/AIDS Topics ICAAC: Declining Prevalence of HIV Triple-class and Protease Inhibitor Resistance
- Details
- Category: HIV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
HIV strains showing resistance to protease inhibitors, or to all 3 of the earliest classes of antiretroviral drugs, have become less common over the past several years, making it easier to construct effective regimens, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
CASCADE Study Finds Benefit of ART Below CD4 Count of 500, But Not Above
- Details
- Category: HIV Treatment
- Published on Friday, 07 October 2011 00:00
- Written by Liz Highleyman
Starting antiretroviral therapy (ART) at CD4 cell counts between 350 and 499 cells/mm3 predicted slower HIV disease progression among participants in the CASCADE cohort, investigators reported in the September 26, 2011, Archives of Internal Medicine. A similar benefit was not apparent, however, for those who started with 500-799 cells/mm3.
Tobira Recruiting for Trial of CCR2/CCR5 Entry Inhibitor Cenicriviroc
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 30 September 2011 00:00
- Written by Press Release
Tobira Therapeutics has initiated a clinical trial to test its investigational CCR2/CCR5 antagonist HIV entry inhibitor cenicriviroc (TBR-652).
ICAAC: Monoclonal Antibody Ibalizumab May Hold Promise for Treatment-Experienced HIV Patients
- Details
- Category: HIV Treatment
- Published on Tuesday, 04 October 2011 00:00
- Written by Liz Highleyman
Ibalizumab (also known as TMB-355, formerly TNX-355) -- an antibody-based therapy for HIV -- was well-tolerated and significantly reduced viral load over 24 weeks when used with optimized background therapy, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
Is the Cure for HIV Possible in our Lifetime? [VIDEO]
- Details
- Category: Search for a Cure
- Published on Sunday, 25 September 2011 00:00
- Written by Video
The Program for Wellness Restoration has produced a short video about the ongoing search for a cure for HIV, including promising approaches under study and what advocates can do to speed up research.
ICAAC: Omitting Inactive NRTIs from Salvage Regimen Can Maintain Viral Suppression
- Details
- Category: HIV Treatment
- Published on Friday, 30 September 2011 00:00
- Written by Liz Highleyman
Simplifying therapy by discontinuing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that no longer demonstrate activity against HIV due to resistance appears to be a safe strategy that does not compromise virological control, according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) this month in Chicago.
Quad Pill Works as Well as Atazanavir Combo at 48 Weeks
- Details
- Category: HIV Treatment
- Published on Friday, 23 September 2011 00:00
- Written by Press Release
The experimental Quad pill -- a once-daily single-tablet regimen containing the integrase inhibitor elvitegravir, the novel boosting agent cobicistat, and the NRTIs tenofovir and emtricitabine -- met a 48-week primary endpoint demonstrating non-inferiority to a boosted atazanavir regimen, Gilead Sciences announced this week. Both combinations suppressed HIV RNA in about 90% of treatment-naive HIV patients, but fewer people discontinued the Quad due to side effects. 
More Articles...
- ICAAC: Cobicistat Matches Ritonavir as Booster, Studies Clarify Effects on Kidney Function
- ICAAC: Zinc Finger Gene Therapy Boosts CD4 Cells, May Lower HIV Viral Load
- ICAAC: Raltegravir is Effective and Well-tolerated in Diverse Populations with HIV
- DHHS Updates Perinatal Antiretroviral Treatment Guidelines
- Darunavir/Ritonavir plus Raltegravir May Not Adequately Suppress High Viral Load
Web Design and Development by